Epizyme Inc. (NASDAQ:EPZM) shot up 2.7% during trading on Tuesday . The company traded as high as $7.80 and last traded at $7.72, with a volume of 96,537 shares changing hands. The stock had previously closed at $7.52.

A number of brokerages have recently commented on EPZM. Zacks Investment Research upgraded Epizyme from a “sell” rating to a “hold” rating in a research report on Wednesday, August 10th. HC Wainwright reiterated a “buy” rating on shares of Epizyme in a research report on Tuesday, August 9th. JMP Securities reiterated a “buy” rating and set a $28.00 price objective on shares of Epizyme in a research report on Thursday, June 23rd. Cowen and Company reiterated a “buy” rating on shares of Epizyme in a research report on Monday, June 20th. Finally, Leerink Swann reiterated an “outperform” rating and set a $39.00 price objective on shares of Epizyme in a research report on Tuesday, June 21st. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus price target of $23.11.

The stock’s market capitalization is $439.31 million. The stock has a 50 day moving average of $9.29 and a 200 day moving average of $10.37.

Epizyme (NASDAQ:EPZM) last released its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.49) EPS for the quarter, topping analysts’ consensus estimates of ($0.52) by $0.03. Equities research analysts predict that Epizyme Inc. will post ($2.19) EPS for the current year.

In other Epizyme news, insider Robert A. Copeland sold 4,000 shares of Epizyme stock in a transaction on Monday, August 1st. The shares were sold at an average price of $10.37, for a total transaction of $41,480.00. Following the completion of the sale, the insider now owns 35,538 shares of the company’s stock, valued at approximately $368,529.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

An institutional investor recently bought a new position in Epizyme stock. California Public Employees Retirement System bought a new position in Epizyme Inc. (NASDAQ:EPZM) during the fourth quarter, according to its most recent filing with the SEC. The firm bought 170,000 shares of the biopharmaceutical company’s stock, valued at approximately $2,723,000. California Public Employees Retirement System owned about 0.41% of Epizyme as of its most recent SEC filing.

Epizyme, Inc is a clinical-stage biopharmaceutical company. The Company discovers, develops and plans to commercialize epigenetic therapies for cancer patients. The Company’s segment is the discovery and development of novel epigenetic therapies for cancer patients. It develops small molecule inhibitors of a class of enzymes known as histone methyltransferases, or HMTs.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.